Clipping of news on Brazilian Culture, Law and Citizenship
1/17/2017
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Transparent image
Six batches of Beige Fluid Base from Stiefel Laboratories presented errors in external packaging.
By: Ascom / Anvisa
Posted: 13/01/2017 14:50
Last Modified: 01/13/2017 14:58
Anvisa suspended the commercial circulation of six batches of Spectraban Light Beige Fluid Base, Spectraban Medium Beige Fluid Base and Spectraban Fluid Translucent Base. The suspension of the lots occurred due to an error in the indication of the UVA factor in the secondary packaging of the products.
The company Laboratorios Stiefel Ltda justified that, although it appears on the secondary packaging marketed of some lots the indication of UVA +++, the option was to register the product with UVA ++. The company also informed that in the act of registering with Anvisa, studies were presented, proving that the protection factor of those products is, in fact, UVA +++.
Since the information on the secondary labels is not in accordance with the Health Surveillance, Anvisa has ordered the suspension of batches 1052457 and 1051042 of the Spectraban Light Beige Fluid Base product lot 1051404, 1051985 and 1052984 of the Spectraban Medium Beige Fluid Base product and Of lot 1052381 of the product Spectraban Translucent Fluid Base.
The company Laboratorios Stiefel Ltda, manufacturer of cosmetics, is responsible for collecting the existing stock in the market, of the lots in question.
Source: Anvisa
Our news is removed in full from our partners' websites. For this reason, we can not change the content of these even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.